基于CT的临床-影像组学列线图预测晚期肝细胞癌患者TACE联合卡瑞利珠单抗与阿帕替尼治疗的总生存期
回顾性纳入150例临床或病理确诊的肝细胞癌患者,分为训练组105例和测试组45例,构建基于CT影像组学评分与独立临床预后因素的临床-影像组学列线图。该列线图预测总生存的C指数为0.840,优于影像组学列线图(0.817)和临床列线图(0.661),1年和2年AUC分别为0.936和0.946,决策曲线分析证实其临床实用性。
要点
- 临床-影像组学列线图预测总生存的C指数为0.840,高于影像组学列线图0.817和临床列线图0.661。
- 列线图1年和2年AUC分别为0.936和0.946。
- 影像组学评分与总生存显著相关(P < 0.001)。
核心结论
- 基于CT的临床-影像组学列线图在预测接受TACE联合卡瑞利珠单抗与阿帕替尼治疗的晚期肝细胞癌患者总生存方面展现出较强潜力。
研究设计与样本
- 回顾性纳入150例临床或病理确诊的肝细胞癌患者,分为训练组(n=105)和测试组(n=45),构建CT影像组学评分并联合独立临床预后因素建立临床-影像组学列线图。
诊断标准与关键数值
- 共筛选出5个CT影像组学特征用于构建影像组学评分。
- 临床-影像组学列线图预测总生存的C指数为0.840,影像组学列线图为0.817,临床列线图为0.661。
- 临床-影像组学列线图1年AUC为0.936,2年AUC为0.946。
- 影像组学评分与总生存显著相关(P < 0.001)。
临床应用与阅片要点
- 作者认为基于CT的临床-影像组学列线图在预测接受TACE联合卡瑞利珠单抗与阿帕替尼治疗的晚期肝细胞癌患者总生存方面展现出较强潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To construct a computed tomography (CT)-based clinical-radiomics nomogram for estimating overall survival (OS) in advanced hepatocellular carcinoma (HCC) patients receiving transcatheter arterial chemoembolization (TACE) in combination with camrelizumab and apatinib.
METHODS: A retrospective recruitment of 150 patients with clinically or pathologically confirmed HCC was conducted, followed by their division into training cohort (n = 105) and test cohort (n = 45). To generate the radiomics score (Rad-score), a series of analyses were performed, including Pearson correlation analysis, univariate Cox analysis, and least absolute shrinkage and selection operator Cox regression analysis. Subsequently, a clinical-radiomics nomogram was constructed using the Rad-score combined with independent clinical prognostic factors, followed by assessments of its calibration, discrimination, reclassification, and clinical utility.
RESULTS: Five CT radiomics features were selected. The Rad-score showed a significant correlation with OS (P < 0.001). The clinical-radiomics nomogram demonstrated superior performance in estimating OS, with a concordance index (C-index) of 0.840, compared to the radiomics nomogram (C-index: 0.817) and the clinical nomogram (C-index: 0.661). It also exhibited high 1-year and 2-year area under the curves of 0.936 and 0.946, respectively. Additionally, the clinical-radiomics nomogram markedly enhanced classification accuracy for OS outcomes, as evidenced by net reclassification improvement and integrated discrimination improvement. Decision curve analysis confirmed its clinical utility.
CONCLUSION: A CT-based clinical-radiomics nomogram exhibits strong potential for predicting OS in advanced HCC patients undergoing TACE combined with camrelizumab and apatinib.
引用
- Ding G, Li K. A CT-Based Clinical-Radiomics Nomogram for Predicting the Overall Survival to TACE Combined with Camrelizumab and Apatinib in Patients with Advanced Hepatocellular Carcinoma. Acad Radiol. 2024. PMID: 39578199. doi:10.1016/j.acra.2024.10.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。